Heart12d
Prognostic impact of neutrophil-to-lymphocyte ratio in patients with and without diabetes mellitus undergoing percutaneous coronary intervention
Background The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation associated with adverse ...
Physician's Weekly4d
Clinical Biomarkers for Assessing Disability in Acute NMOSD
The following is a summary of “Acute neuromyelitis optica spectrum disorder patients’ clinical analysis of disability-related ...
Astronauts' Health During Space Missions: Nichi BRITE And Neu REFIX Beta Glucans Could Benefit By Neutrophil-To-Lymphocy...
Neutrophil to Lymphocyte ratio (NLR) is a critical biomarker of health of astronauts during space mission, and that of aging ...
The American Journal of Managed Care7d
Systemic Immune Response Index Identified as Independent Risk Factor for COPD
The systemic immune response index outperformed other inflammatory markers in predicting chronic obstructive pulmonary ...
MedPage Today7d
NCD for Tricuspid Valve Procedures; Flavanols & BP; Infective Endocarditis Up
(JAMA Network Open) The neutrophil-to-lymphocyte ratio, a marker of systemic inflammation, had prognostic value in people undergoing percutaneous coronary intervention. (Heart) Operators had less ...
Cancer Therapy Advisor13h
Imfinzi Approved as Perioperative Treatment for MIBC
The FDA has approved Imfinzi (durvalumab) as neoadjuvant and adjuvant treatment in patients with muscle-invasive bladder cancer.
The American Journal of Managed Care11d
Bimekizumab Reduces Inflammation, Cardiovascular Risk
Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...
MPR22h
Imfinzi Combo Therapy Approved for Muscle-Invasive Bladder Cancer
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...